Dr. Reddy’s receives EIR from USFDA for Miryalaguda facility

14 Jun 2017 Evaluate

Dr. Reddy’s Laboratories has received an Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) as closure of audit for Miryalaguda facility. Miryalaguda plant supplies active ingredients for company’s captive consumption as well as for its customers.

Earlier in February, the USFDA had conducted an audit of API manufacturing plant at Miryalaguda, wherein the company was issued a form 483 with three observations for the said facility.

Dr. Reddy’s Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.


Dr. Reddys Lab Share Price

1218.40 9.95 (0.82%)
30-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1595.00
Dr. Reddys Lab 1218.40
Cipla 1323.95
Zydus Lifesciences 885.20
Lupin 2151.05
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×